|
| Press Releases |
|
 |
|
| Friday, April 13, 2018 |
|
|
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago |
| Eisai Co., Ltd. announced today that it has entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University, and the University of Chicago to develop a potential new treatment for tuberculosis (TB). more info >> |
|
| Monday, April 2, 2018 |
|
|
Eisai Submits Supplemental New Drug Application to U.S. FDA |
| Eisai Co., Ltd. has announced that it has submitted to the U.S. FDA a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) seeking approval for an indication expansion to cover pediatric patients with epilepsy. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement |
| Eisai Co., Ltd. and Nichi-Iko Pharmaceutical announced today that they have entered into a strategic alliance agreement as well as a share transfer agreement for a capital and business alliance. more info >> |
|
| Friday, March 23, 2018 |
|
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal |
| AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis. With this approval, HUMIRA has been approved for 10 indications in Japan. more info >> |
|
|
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA has been approved in Japan for unresectable hepatocellular carcinoma (HCC). more info >> |
|
| Wednesday, March 14, 2018 |
|
|
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary Eisai China Inc. has launched the gastrointestinal prokinetic agent Cidine in China. more info >> |
|
| Thursday, March 8, 2018 |
|
|
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., today announced that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai. more info >> |
|
|
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced positive topline results from multiple studies of lemborexant, an investigational agent for sleep and wake regulation currently being studied for the treatment of multiple sleep disorders. more info >> |
|
| Tuesday, February 27, 2018 |
|
|
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan |
| Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today. more info >> |
|
| Wednesday, February 21, 2018 |
|
|
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500) |
| Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Spectral Capital Announces Transformation into a Deep Quantum Technology Platform 
Dec 25, 2024 10:59 HKT/SGT
|
|
|
Singapore's most anticipated skyhigh destination C.O.T.U officially opens in iconic Marina Bay this holiday season
Dec 25, 2024 08:00 HKT/SGT
|
|
|
From Visionary Talks to Futuristic Robots: VAP Group's Global Blockchain Show Dazzles Dubai
Dec 25, 2024 07:36 HKT/SGT
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 25, 2024 07:25 HKT/SGT
|
|
|
VAP Group's Global AI Show Explores the Future of AI with Over 3,000 Participants
Dec 24, 2024 15:40 HKT/SGT
|
|
|
The 25th World LNG Summit & Awards will take place on 2-5 December 2025 in Istanbul, Turkiye
Dec 24, 2024 15:30 HKT/SGT
|
|
|
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence
Dec 24, 2024 15:20 HKT/SGT
|
|
|
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
|
|
|
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
|
|
|
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
|
|
|
Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations
Dec 24, 2024 10:54 JST
|
|
|
GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST
|
|
|
Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST
|
|
|
Kincora Announces Closing of Private Placement, Performance Rights Exercise and Shares for Services
Dec 24, 2024 06:59 HKT/SGT
|
|
|
Revolutionize Your Business Plan: How Ai is Making Entrepreneurship Easier
Dec 23, 2024 21:48 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
